References
- Baillie TA, Cayen MN, Hassan F, Gerson RJ, Green JD, Grossman SJ, Klunk LJ, Lebanc B, Perkins DG, Shipley LA. 2002. Metabolites in safety testing. Toxicology and Applied Pharmacology 182:188–196.
- Camilleri M, Choi, M. 1997. The therapeutic potential of 5-HT3 receptor antagonists in the treatment of irritable bowel syndrome. Aliment Pharmacology 11:3–15.
- Cremoni F, Delgado-Aros S, Camilleri M. 2003. Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomised trials. Neurogastroenterology and Motility 15:79–86.
- Humphrey PPA, Bountra C, Clayton N, Kozlowski K. 1999. The therapeutic potential of 5-HT3 receptor antagonists in the treatment of irritable bowel syndrome. Alimentary Pharmacology and Therapy 13:31-38. Knaggs AR, Cable 1K1\4, Connell RJP, Sidebottom PJ, Wells GN, Sutherland DR. 1995. Biotansformation of alosetron: mechanism of hydantoin formation. Tetrahedron Letters 36:477–480.
- Olden KW. 2002. Diagnosis of irritable bowel syndrome. Gastroenterology 122:1701–1714.
- Prior A, Read NW. 1993. Reduction of rectal sensitivity and post-prandial motility by granisetron, a 5 HT3-receptor antagonist, in patients with irritable bowel syndrome. Alimentary Pharmacology and Therapy 7: 175–180.
- Ringel Y, Sperber AD, Drossman DA. 2001. Irritable bowel syndrome. Annual Reviews in Medicine 52:319–338.
- Saito YA, Schoenfeld P, Locke GR III. 2002. The epidemiology of irritable bowel syndrome in North America: a systematic review. American Journal in Gastroenterology 97:1910–1915.
- Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Muller-Lissner SA. 1999. Functional bowel disorders and functional abdominal pain. Gut 45\(Suppl. 2): 1143–1147.
- Wolfe S, Chey WY, Washington MK, Harding J, Heath AT, McSorley DJ, Dukes GE, Hunt CM. 2001. Tolerability and safety of alosetron during long term administration in female and male irritable bowel syndrome patients. American Journal of Gastroenterology 96:803–811.